CapsoVision, Inc.

CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CV stands at 328.3M. In comparison, SIRO has a market cap of 22B. Regarding current trading prices, CV is priced at $6.57, while SIRO trades at $109.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CV currently has a P/E ratio of -6.20, whereas SIRO's P/E ratio is N/A. In terms of profitability, CV's ROE is +1.27%, compared to SIRO's ROE of +0.14%. Regarding short-term risk, CV is more volatile compared to SIRO. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check SIRO's competition here

CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CV stands at 328.3M. In comparison, HIMS has a market cap of 4.9B. Regarding current trading prices, CV is priced at $6.57, while HIMS trades at $22.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CV currently has a P/E ratio of -6.20, whereas HIMS's P/E ratio is -249.28. In terms of profitability, CV's ROE is +1.27%, compared to HIMS's ROE of -0.02%. Regarding short-term risk, CV is more volatile compared to HIMS. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check HIMS's competition here

CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CV stands at 328.3M. In comparison, NVST has a market cap of 3.7B. Regarding current trading prices, CV is priced at $6.57, while NVST trades at $23.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CV currently has a P/E ratio of -6.20, whereas NVST's P/E ratio is 56.20. In terms of profitability, CV's ROE is +1.27%, compared to NVST's ROE of +0.02%. Regarding short-term risk, CV is more volatile compared to NVST. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check NVST's competition here

CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CV stands at 328.3M. In comparison, NAKA has a market cap of 3.4B. Regarding current trading prices, CV is priced at $6.57, while NAKA trades at $0.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CV currently has a P/E ratio of -6.20, whereas NAKA's P/E ratio is -0.36. In terms of profitability, CV's ROE is +1.27%, compared to NAKA's ROE of -0.85%. Regarding short-term risk, CV is more volatile compared to NAKA. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check NAKA's competition here

CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CV stands at 328.3M. In comparison, CON has a market cap of 3.3B. Regarding current trading prices, CV is priced at $6.57, while CON trades at $25.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CV currently has a P/E ratio of -6.20, whereas CON's P/E ratio is 18.37. In terms of profitability, CV's ROE is +1.27%, compared to CON's ROE of +0.46%. Regarding short-term risk, CV is more volatile compared to CON. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check CON's competition here

CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CV stands at 328.3M. In comparison, BBNX has a market cap of 418.9M. Regarding current trading prices, CV is priced at $6.57, while BBNX trades at $9.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CV currently has a P/E ratio of -6.20, whereas BBNX's P/E ratio is -6.86. In terms of profitability, CV's ROE is +1.27%, compared to BBNX's ROE of -0.23%. Regarding short-term risk, CV is more volatile compared to BBNX. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check BBNX's competition here

CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CV stands at 328.3M. In comparison, KDLY has a market cap of 68.1M. Regarding current trading prices, CV is priced at $6.57, while KDLY trades at $11.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CV currently has a P/E ratio of -6.20, whereas KDLY's P/E ratio is -15.48. In terms of profitability, CV's ROE is +1.27%, compared to KDLY's ROE of -0.85%. Regarding short-term risk, CV is more volatile compared to KDLY. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check KDLY's competition here

CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CV stands at 328.3M. In comparison, NEUE has a market cap of 60.9M. Regarding current trading prices, CV is priced at $6.57, while NEUE trades at $6.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CV currently has a P/E ratio of -6.20, whereas NEUE's P/E ratio is -0.38. In terms of profitability, CV's ROE is +1.27%, compared to NEUE's ROE of +0.09%. Regarding short-term risk, CV is more volatile compared to NEUE. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check NEUE's competition here

CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CV stands at 328.3M. In comparison, PARK has a market cap of 36.5M. Regarding current trading prices, CV is priced at $6.57, while PARK trades at $18.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CV currently has a P/E ratio of -6.20, whereas PARK's P/E ratio is -104.39. In terms of profitability, CV's ROE is +1.27%, compared to PARK's ROE of -0.24%. Regarding short-term risk, CV is more volatile compared to PARK. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check PARK's competition here

CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CV stands at 328.3M. In comparison, BRK has a market cap of 11.6M. Regarding current trading prices, CV is priced at $6.57, while BRK trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CV currently has a P/E ratio of -6.20, whereas BRK's P/E ratio is N/A. In terms of profitability, CV's ROE is +1.27%, compared to BRK's ROE of N/A. Regarding short-term risk, CV is more volatile compared to BRK. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check BRK's competition here

CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CV stands at 328.3M. In comparison, PFSA has a market cap of 225.2K. Regarding current trading prices, CV is priced at $6.57, while PFSA trades at $0.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CV currently has a P/E ratio of -6.20, whereas PFSA's P/E ratio is N/A. In terms of profitability, CV's ROE is +1.27%, compared to PFSA's ROE of +1.54%. Regarding short-term risk, CV is less volatile compared to PFSA. This indicates potentially lower risk in terms of short-term price fluctuations for CV.Check PFSA's competition here

CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CV stands at 328.3M. In comparison, SPNC has a market cap of 0. Regarding current trading prices, CV is priced at $6.57, while SPNC trades at $38.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CV currently has a P/E ratio of -6.20, whereas SPNC's P/E ratio is N/A. In terms of profitability, CV's ROE is +1.27%, compared to SPNC's ROE of -0.61%. Regarding short-term risk, CV is more volatile compared to SPNC. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check SPNC's competition here

CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CV stands at 328.3M. In comparison, MZOR has a market cap of 0. Regarding current trading prices, CV is priced at $6.57, while MZOR trades at $58.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CV currently has a P/E ratio of -6.20, whereas MZOR's P/E ratio is N/A. In terms of profitability, CV's ROE is +1.27%, compared to MZOR's ROE of -0.14%. Regarding short-term risk, CV is more volatile compared to MZOR. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check MZOR's competition here

CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CV stands at 328.3M. In comparison, PMC has a market cap of 0. Regarding current trading prices, CV is priced at $6.57, while PMC trades at $29.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CV currently has a P/E ratio of -6.20, whereas PMC's P/E ratio is N/A. In terms of profitability, CV's ROE is +1.27%, compared to PMC's ROE of +0.04%. Regarding short-term risk, CV is more volatile compared to PMC. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check PMC's competition here

CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CV stands at 328.3M. In comparison, SCAI has a market cap of 0. Regarding current trading prices, CV is priced at $6.57, while SCAI trades at $55.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CV currently has a P/E ratio of -6.20, whereas SCAI's P/E ratio is N/A. In terms of profitability, CV's ROE is +1.27%, compared to SCAI's ROE of +0.09%. Regarding short-term risk, CV is more volatile compared to SCAI. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check SCAI's competition here

CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CV stands at 328.3M. In comparison, STJ has a market cap of 0. Regarding current trading prices, CV is priced at $6.57, while STJ trades at $80.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CV currently has a P/E ratio of -6.20, whereas STJ's P/E ratio is N/A. In terms of profitability, CV's ROE is +1.27%, compared to STJ's ROE of +0.21%. Regarding short-term risk, CV is more volatile compared to STJ. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check STJ's competition here

CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CV stands at 328.3M. In comparison, DSCI has a market cap of 0. Regarding current trading prices, CV is priced at $6.57, while DSCI trades at $7.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CV currently has a P/E ratio of -6.20, whereas DSCI's P/E ratio is N/A. In terms of profitability, CV's ROE is +1.27%, compared to DSCI's ROE of -0.00%. Regarding short-term risk, CV is more volatile compared to DSCI. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check DSCI's competition here

CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CV stands at 328.3M. In comparison, AMSG has a market cap of 0. Regarding current trading prices, CV is priced at $6.57, while AMSG trades at $67.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CV currently has a P/E ratio of -6.20, whereas AMSG's P/E ratio is N/A. In terms of profitability, CV's ROE is +1.27%, compared to AMSG's ROE of +0.08%. Regarding short-term risk, CV is more volatile compared to AMSG. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check AMSG's competition here

CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CV stands at 328.3M. In comparison, SPAN has a market cap of 0. Regarding current trading prices, CV is priced at $6.57, while SPAN trades at $29.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CV currently has a P/E ratio of -6.20, whereas SPAN's P/E ratio is N/A. In terms of profitability, CV's ROE is +1.27%, compared to SPAN's ROE of +0.17%. Regarding short-term risk, CV is less volatile compared to SPAN. This indicates potentially lower risk in terms of short-term price fluctuations for CV.Check SPAN's competition here

CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CV stands at 328.3M. In comparison, EXAC has a market cap of 0. Regarding current trading prices, CV is priced at $6.57, while EXAC trades at $49.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CV currently has a P/E ratio of -6.20, whereas EXAC's P/E ratio is N/A. In terms of profitability, CV's ROE is +1.27%, compared to EXAC's ROE of +0.00%. Regarding short-term risk, CV is more volatile compared to EXAC. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check EXAC's competition here

CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CV stands at 328.3M. In comparison, ABAX has a market cap of 0. Regarding current trading prices, CV is priced at $6.57, while ABAX trades at $83.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CV currently has a P/E ratio of -6.20, whereas ABAX's P/E ratio is N/A. In terms of profitability, CV's ROE is +1.27%, compared to ABAX's ROE of +0.10%. Regarding short-term risk, CV is more volatile compared to ABAX. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check ABAX's competition here

CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CV stands at 328.3M. In comparison, COTV has a market cap of 0. Regarding current trading prices, CV is priced at $6.57, while COTV trades at $44.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CV currently has a P/E ratio of -6.20, whereas COTV's P/E ratio is N/A. In terms of profitability, CV's ROE is +1.27%, compared to COTV's ROE of +0.14%. Regarding short-term risk, CV is more volatile compared to COTV. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check COTV's competition here

CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CV stands at 328.3M. In comparison, LDR has a market cap of 0. Regarding current trading prices, CV is priced at $6.57, while LDR trades at $67.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CV currently has a P/E ratio of -6.20, whereas LDR's P/E ratio is N/A. In terms of profitability, CV's ROE is +1.27%, compared to LDR's ROE of +1.17%. Regarding short-term risk, CV is more volatile compared to LDR. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check LDR's competition here

CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CV stands at 328.3M. In comparison, LPNT has a market cap of 0. Regarding current trading prices, CV is priced at $6.57, while LPNT trades at $64.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CV currently has a P/E ratio of -6.20, whereas LPNT's P/E ratio is N/A. In terms of profitability, CV's ROE is +1.27%, compared to LPNT's ROE of +0.05%. Regarding short-term risk, CV is more volatile compared to LPNT. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check LPNT's competition here

CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CV stands at 328.3M. In comparison, MEDC has a market cap of 0. Regarding current trading prices, CV is priced at $6.57, while MEDC trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CV currently has a P/E ratio of -6.20, whereas MEDC's P/E ratio is N/A. In terms of profitability, CV's ROE is +1.27%, compared to MEDC's ROE of N/A. Regarding short-term risk, CV is less volatile compared to MEDC. This indicates potentially lower risk in terms of short-term price fluctuations for CV.Check MEDC's competition here

CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CV stands at 328.3M. In comparison, EVHC has a market cap of 0. Regarding current trading prices, CV is priced at $6.57, while EVHC trades at $45.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CV currently has a P/E ratio of -6.20, whereas EVHC's P/E ratio is N/A. In terms of profitability, CV's ROE is +1.27%, compared to EVHC's ROE of +0.07%. Regarding short-term risk, CV is more volatile compared to EVHC. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check EVHC's competition here

CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CV stands at 328.3M. In comparison, ABCO has a market cap of 0. Regarding current trading prices, CV is priced at $6.57, while ABCO trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CV currently has a P/E ratio of -6.20, whereas ABCO's P/E ratio is N/A. In terms of profitability, CV's ROE is +1.27%, compared to ABCO's ROE of +0.19%. Regarding short-term risk, CV is more volatile compared to ABCO. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check ABCO's competition here

CV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CV stands at 328.3M. In comparison, CYNO has a market cap of 0. Regarding current trading prices, CV is priced at $6.57, while CYNO trades at $66.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CV currently has a P/E ratio of -6.20, whereas CYNO's P/E ratio is N/A. In terms of profitability, CV's ROE is +1.27%, compared to CYNO's ROE of +0.03%. Regarding short-term risk, CV is more volatile compared to CYNO. This indicates potentially higher risk in terms of short-term price fluctuations for CV.Check CYNO's competition here